Metabolic Responses of Metformin and Genetic Polymorphisms of SLC22A1 Gene in PCOS
Polycystic Ovary Syndrome, Metformin
About this trial
This is an interventional treatment trial for Polycystic Ovary Syndrome focused on measuring Metformin, solute carrier family 22 member 1, Polycystic ovary syndrome, Metabolic response
Eligibility Criteria
Inclusion Criteria: • Newly diagnosed women of reproductive age (18 - 35 years) PCOS patients Exclusion Criteria: • Patients having known similar endocrine disorders (hypothyroidism, hyperprolactinemia, androgen producing tumor, congenital adrenal hyperplasia, etc) Planning to conceive within next six months, pregnant/ lactating mother Patients with known diabetes mellitus, ischemic heart disease, chronic liver (serum ALT >2 × upper limit of normal) and renal disease (eGFR <60 ml/minute/1.73 m2 body surface area) Patients taking oral contraceptive, steroid or drugs affecting insulin resistance (metformin, pioglitazone)
Sites / Locations
- Department of Endocrinology, Bangabandhu Sheikh Mujib Medical UniversityRecruiting
Arms of the Study
Arm 1
Experimental
PCOS
Participants with PCOS